PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

E-ISSN： 1873-4286|19|21|3869-3877

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.21, 2013-01, pp. : 3869-3877

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

By Wierzbicki Anthony S Hardman Timothy C Viljoen Adie

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 667-676

Informa Healthcare

Access to resources Recommend Favorite

The therapeutic potential of PCSK9 inhibition in primary dyslipidemia, the example from SAR236553/REGN727

By Salam Amar M

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1585-1588

Informa Healthcare

Access to resources Recommend Favorite

Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells

Current Pharmaceutical Biotechnology, Vol. 11, Iss. 8, 2010-12 ,pp. : 895-905

Bentham Science Publishers

Access to resources Recommend Favorite

Malonyl-CoA Decarboxylase Inhibition as a Novel Approach to Treat Ischemic Heart Disease

By Lopaschuk Gary Stanley William

Cardiovascular Drugs and Therapy, Vol. 20, Iss. 6, 2006-12 ,pp. : 433-439

Springer Publishing Company

Access to resources Recommend Favorite

PARP inhibition: a novel approach to treat ischaemia/reperfusion and inflammation-related injuries

By Zhang J.

Expert Opinion on Emerging Drugs, Vol. 4, Iss. 1, 1999-01 ,pp. : 209-221

Informa Healthcare

Access to resources Recommend Favorite